XML 37 R27.htm IDEA: XBRL DOCUMENT

Significant agreements (Tables)

9 Months Ended

Sep. 30, 2022

Significant agreements.

Summary of revenue recognized from collaboration arrangements


		Three Months						Nine Months
		Ended						Ended
		September 30,						September 30,
		2022			2021			2022			2021
Collaboration revenues
Ionis		$	2,195		$	2,066		$	6,764		$	2,066
Genentech			798			1,063			3,144			4,142
Dementia Discovery Fund			47			77			205			314
AstraZeneca			—			1,127			1,165			1,404
Total collaboration revenues		$	3,040		$	4,333		$	11,278		$	7,926

Summary of changes in the balances of the Company's contract assets and liabilities

The following table presents changes in the balances of the Company’s contract assets and liabilities (in thousands):


		Beginning Balance									Impact of			Ending Balance
		January 1,									Exchange			September 30,
		2022			Additions			Deductions			Rates			2022
Contract liabilities:
Deferred revenue
Ionis collaboration deferred revenue		$	34,115		$	—		$	(6,764)		$	(5,190)		$	22,161
Genentech collaboration deferred revenue			34,436			10,000			(3,144)			(6,475)			34,817
DDF collaboration deferred revenue			428			—			(205)			(53)			170
AstraZeneca collaboration deferred revenue			2,361			—			(1,165)			(204)			992
Total deferred revenue		$	71,340		$	10,000		$	(11,278)		$	(11,922)		$	58,140


		Beginning Balance									Impact of			Ending Balance
		January 1,									Exchange			December 31,
		2021			Additions			Deductions			Rates			2021
Contract liabilities:
Deferred revenue
Ionis collaboration deferred revenue		$	3,000		$	36,002		$	(4,242)		$	(645)		$	34,115
Genentech collaboration deferred revenue			27,579			13,000			(5,660)			(483)			34,436
DDF collaboration deferred revenue			821			—			(391)			(2)			428
AstraZeneca collaboration deferred revenue			3,756			54			(1,404)			(45)			2,361
Total deferred revenue		$	35,156		$	49,056		$	(11,697)		$	(1,175)		$	71,340

Summary of recognition of revenues as a result of changes in contract asset and contract liability balances

During the three and nine months ended September 30, 2022 and 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2022			2021			2022			2021
Revenue recognized in the period from:
Revenue recognized based on proportional performance	$	3,040		$	3,206		$	10,072		$	6,263
Revenue recognized based on expiration of material rights		—			1,127			1,206			1,507
Revenue recognized based on changes in transaction price		—			—			—			156
Total	$	3,040		$	4,333		$	11,278		$	7,926

Significant agreements.

Summary of allocation of transaction price to separate performance obligations


		Allocation of
Performance Obligations		Transaction Price
Combined licenses and research and discovery performance obligation		$	34,100
Four material rights associated with credits for IND Acceptance fees			3,900
		$	38,000

Significant agreements.

Summary of allocation of transaction price to separate performance obligations


		Allocation of
Performance Obligations		Transaction Price
Genentech Collaboration Program #1 Performance Obligation		$	4,019
Genentech Collaboration Program #2 Performance Obligation			8,037
Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1			352
Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2			12,400
Material rights associated with limited substitution rights			1,187
Two material rights for Expansion Options			7,005
		$	33,000

Significant agreements.

Summary of allocation of transaction price to separate performance obligations


		Allocation of
Performance Obligations		Transaction Price
Target Three Research License and Related Services		$	650
Target 3 Material Right			1,504
Target 4 Material Right			1,204
Target 5 Material Right			1,165
Target 6 Material Right			1,127
		$	5,650